Correlations of inhaled NO with the cTnI levels and the plasma clotting factor in rabbits with acute massive pulmonary embolism

Abstract Purpose: To investigate the correlation of inhaled nitric oxide (NO) on plasma levels of cardiac troponin I (cTnI) and von Willebrand factor (vWF), glycoprotein (GP) IIb/IIIa, granule membrane protein 140 (GMP-140) in rabbits with acute massive pulmonary embolism (PE). Methods: Thirty apanese white rabbits were divided into 3 groups, thrombus were injected in model group (n = 10), NO were inhalated for 24 h after massive PE in NO group (n = 10), saline were injected in control group (n = 10). The concentrations of vWF, GP IIb/IIIa, GMP-140 and cTnI were tested at 4, 8, 12, 16, 20, and 24 h, Correlation analyses were conducted between cTnI and vWF, GP IIb/IIIa, and GMP-140 by Pearson's correlation. Results: The concentration of cTnI and vWF, GP IIb/IIIa, and GMP-140 was increased in the model group, compared to control group. In the inhaled group, the concentrations of cTnI, vWF, GP IIb/IIIa, and GMP-140 were reduced compared to model group. There was a positive correlation between cTnI and vWF, GP IIb/IIIa, and GMP-140. Conclusion: Inhaled nitric oxide can lead to a decrease in levels of cardiac troponin I, von Willebrand factor, glycoprotein, and granule membrane protein 140, after an established myocardial damage, provoked by acute massive pulmonary embolism.

Estudo experimental do uso de um antagonista do receptor da glicoproteína IIb/IIIa das placentas na prevençäo de tromboses em microanastomoses vasculares / An experimental study on the use of an antagonist of the platelet glycoprotein IIb/IIIa receptor in the prevention of thrombosis in vascular microanastomoses

O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevençäo da trombose nas microanastamoses arteriais em ratos Wistar.Utilizou 20 animais, dos quais 10, do grupo controle, receberam soluçäo salina e 10 receberam abciximab, na concentraçäo de 0, 8mg/Kg, injetados na veia femoral.Trinta minutos após a administraçäo da soluçäo salina ou abciximab, todos os animais foram submetidos ao mecanismo provocador de trombose vascular da artéria femoral do lado oposto ao utilizado para administraçäo da droga, por meio de um trauma externo promovido por aparelho IMPACTOR, desenvolvido pela New York University para padronizaçäo de lesäo da medula nervosa, o que padronizou a lesäo arterial. Todos os animais foram submetidos à microanastomose vascular com mononáilon 10-0, em pontos separados, no local do trauma externo.Foram realizados testes para analisar a perviabilidade vascular da artéria femoral no peíodo de 10, 20 e 30 minutos após o término da anastomose. Após este período, todas as artérias femorais submetidas à microanastomoses foram ressecadas e analisadas em microscopia óptica para avaliar a presença de formaçäo de trombos.Após a análise estatística dos dados, o autor conclui que o uso do antagonista do receptor da glicoproteína IIb/IIIa das plaquetas diminui a incidência de tromboses nas microanastomoses vasculares.